Starting a New Study
Work Package 1 (WP1) has the aim to deliver a comprehensive understanding of the epidemiology, risk factors and burden of vaccine-preventable diseases in ageing adults across European countries, via a consistent, comprehensive data collection approach that builds on and extends existing information.
Performing multiple researches at once
On the 3rd of July, the ethical committee approved the protocol for the retrospective pilot studies. The protocol has been written by WP1 under the leadership of Alejandro Orrico Sánchez from FISABIO. At the moment the team is busy developing a statistical analysis plan. The pilot studies will assess the disease and economic burden of pneumococcal pneumonia and invasive extra-intestinal pathogenic Escherichia coli disease. The team will use the SSI database from Denmark and the FISABIO database from the Valencia region in Spain for this assessment. Both databases cover about 4 million individuals. The study will be performed retrospectively over the period of time 2010 until 2018. The two databases have high potential of capturing a near-complete picture, even though the regions are significantly different in terms of data sources and healthcare organization. In addition, the team has the intention to investigate the use of the Q-TWIST methodology to estimate Quality of Life from databases by using the FISABIO database. The data requests have already been made to access providers, however delays are expected since data providers are currently prioritizing COVID-related requests.
AEQUI study
At the 21st of September, the ‘Aged European population Quality of Life in Infectious diseases (AEQUI) study was initiated during a kick-off meeting. The study is led and sponsored by the SANOFI-PASTEUR. The study team aims to measure the impact of Acute Respiratory Infection and bacteremia hospitalizations on Quality of Life and frailty in the elderly population. The AEQUI study consists of a longitudinal prospective case-control study. It will involve almost 4000 hospitalized patients aged 65 years or older who are presenting with bacteremia with positive blood culture and/or Severe Acute Respiratory Infection (SARI). The countries selected for this study are France, Italy and Spain. The Quality of Life and frailty measurements will be based on the EQ5D-3L and the multidimensional prognostic index, respectively. The enrollment of the patients will start in the three participating countries from 1st December.
